23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.

23andMe Holding Co.

Lemonaid Health (part of 23andMe)

23andMe, headquartered in Sunnyvale, CA, is a leading consumer genetics and research company. Founded in 2006, the company’s mission is to help people access, understand, and benefit from the human genome. 23andMe has pioneered direct access to genetic information as the only company with multiple FDA authorizations for genetic health risk reports. The company has created the world’s largest crowdsourced platform for genetic research, with 80 percent of its customers electing to participate. The 23andMe research platform has generated more than 180 publications on the genetic underpinnings of a wide range of diseases, conditions, and traits. The platform also powers the 23andMe Therapeutics group, currently pursuing drug discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory, and cardiovascular diseases, in addition to other therapeutic areas. 23andMe was named as one of the San Francisco Chronicle's Top Workplaces and one of Comparably's Best Places to Work in 2022. CEO, Anne Wojcicki was also named one of Glassdoor’s top CEOs in 2019 and one of Comparably’s "Best CEOs for Women" in 2021 and 2022. More information is available at www.23andMe.com.

Doctor On Demand

GlaxoSmithKline

Casdin Capital

Fidelity

Fidelity Management and Research Company

Foresite Capital

Altimeter Capital

Anne Wojcicki

Richard Branson

Sean Tiner

Future Planet Capital

Raj Luhar

SharesPost Investment Management

NewView Capital

Pegasus Tech Ventures

Sequoia Capital

ACE & Company

Rancilio Cube

23andMe

This #BlackHistoryMonth, we’re sharing quotes from Black leaders in STEM who continue to inspire us every day. Mae Jemison became the first African-American woman to travel into space when she served as a mission specialist aboard the Space Shuttle Endeavour in 1992.

We’re looking for a Sr. Scientist II to join our Research Team! In this role, you will have the opportunity to provide scientific input and strategic direction for research initiatives involving the lung cancer cohort. https://lnkd.in/guC-u3bT

Earlier this year, researchers with the National Institutes of Health, in collaboration with 23andMe and about a dozen other groups, published the largest to-date genetic study of Parkinson’s disease. This is the first large-scale genetics study of Parkinson’s disease to include data from individuals from multiple ancestral populations. 

https://23and.me/3SmIqHS

We are excited to announce the U.S. FDA has cleared the investigational new drug application for 23ME-01473 (‘1473), a natural killer (NK) cell activator intended to treat cancer.

“This program further validates the 23andMe database as a proven resource for identifying novel therapeutic targets,” said Jennifer Low, Head of Therapeutics Development, 23andMe. “The team is excited to initiate our next immuno-oncology program, ‘1473, which is particularly interesting given its two mechanisms of action, which may synergise to enhance NK and T cell immunity against certain tumors.” 

Read more here: https://lnkd.in/gKQMP6Ka

Has there ever been a time – maybe during a stressful moment, or even just out of the blue – when you started to feel dizzy, like your vision was narrowing, and like you were disconnected from your body? 

About 1 in 3 people will experience a panic attack in their lifetime. Panic attacks happen when fear and anxiety overwhelm a person and lead to physical symptoms such as a racing heart, stomach aches, or shortness of breath. 

Our 23andMe+ Premium Panic Attacks report (Powered by 23andMe Research) helps individuals better understand their genetic likelihood of developing panic attacks throughout their lifetime. https://23and.me/426saOl

We're excited to share that the FDA  included our BRCA1/BRCA2 (Selected Variants) Genetic Health Risk Report clearance and PCCP in their 2023 Annual Report for device innovation. 

Check out the report here: https://lnkd.in/evgJZnXh

January is Thyroid Awareness Month. In 2022, we released a 23andMe+ Premium report on Hashimoto’s disease, powered by 23andMe research. 

Hashimoto’s disease is an autoimmune condition in which the immune system causes the thyroid gland to become inflamed and damaged, and over time produce less thyroid hormone. This condition can cause many different symptoms like fatigue or depression, and if left untreated, can be associated with other health conditions like heart problems. 

Members can learn about their genetic likelihood of developing it and actions they can take to promote thyroid and immune health. https://23and.me/3u87E3n

Our very own Dr. Noura Abul-Husn is speaking at the Precision Medicine World Conference this week in Silicon Valley on January 25th! If you’re planning to attend make sure you stop by for her showcase.

At 23andMe, we believe the ability to identify, recruit, and characterize research participants based on genetics unknown to them is a critical capability for our therapeutics and research teams to inform drug development and genetics research.

https://23and.me/48zaTQv

When Emily decided to do a 23andMe, she expected to learn more about her health, genealogy, and all of the “fun stuff DNA can tell you,” but her results led to something unexpected, and expanded what she understood about herself and her family. 

https://23and.me/3HnVW7O

	Mar '19	Mar '20	Mar '21	Mar '22	Mar '23	Mar '24
average inventory				8.51M -	10.52M 23.54%	11.36M 7.97%
average payables				25.10M -	25.43M 1.30%	12.25M 51.83%
average receivables				2.93M -	2.64M 9.96%	5.49M 107.92%
book value per share	0.77 -		-1.47 -	2.53 272.82%	1.58 37.57%	0.40 74.95%
capex per share	-0.07 -	-0.18 164.34%	-0.02 89.98%	-0.04 113.02%	-0.03 35.22%	0.00 109.47%
capex to depreciation	-2.81 -	-3.16 12.37%	-0.36 88.47%	-0.53 46.72%	-0.31 42.04%	0.04 112.36%
capex to operating cash flow	0.28 -	0.40 39.61%	0.10 74.93%	0.08 15.66%	0.07 18.39%	-0.01 110.05%
capex to revenue	-0.06 -	-0.24 281.52%	-0.03 87.45%	-0.05 69.99%	-0.04 26.55%	0.01 113.62%
cash per share	1.11 -		0.70 -	1.53 120.14%	0.86 44.00%	0.46 46.57%
days of inventory on hand	19.36 -		17.94 -	28.34 57.95%	22.67 20.02%	37.83 66.89%
days payables outstanding	64.64 -		35.29 -	99.64 182.33%	28.59 71.31%	35.12 22.83%
days sales outstanding	8.77 -		3.71 -	4.54 22.22%	2.31 49.05%	15.08 552.31%
debt to assets			0.21 -	0.07 63.86%	0.09 20.80%	0.02 75.76%
debt to equity			-0.16 -	0.09 159.90%	0.12 26.76%	0.05 61.51%
dividend yield
earnings yield	-0.05 -	-0.07 57.64%	-0.04 38.93%	-0.16 254.06%	-0.30 92.74%	-0.13 56.10%
enterprise value	3.53B -		3.94B -	917.78M 76.73%	727.88M 20.69%	4.88B 569.81%
enterprise value over ebitda	-19.74 -		-23.91 -	-3.52 85.29%	-2.53 28.01%	-16.70 559.81%
ev to operating cash flow	-35.98 -		-53.12 -	-5.50 89.64%	-4.40 20.00%	-29.67 574.18%
ev to sales	8.01 -		16.17 -	3.38 79.13%	2.43 28.00%	22.20 813.33%
free cash flow per share	-0.31 -	-0.64 105.92%	-0.20 68.53%	-0.50 149.00%	-0.39 21.75%	-0.37 6.60%
free cash flow yield	-0.03 -	-0.07 105.92%	-0.02 69.67%	-0.13 561.18%	-0.17 31.45%	-0.03 79.80%
graham net net	0.21 -		-1.87 -	0.90 148.01%	0.36 59.38%	0.05 86.02%
graham number	2.80 -		3.86 -	5.86 51.80%	4.96 15.36%	3.53 28.71%
income quality	0.53 -	0.74 38.52%	0.40 45.39%	0.77 89.69%	0.53 30.82%	0.25 53.56%
intangibles to total assets	0.00 -	0 100%	0.02 Infinity%	0.38 2,379.54%	0.44 15.94%	0.14 68.94%
interest coverage				-917.52 -	33.81 103.69%
interest debt per share			0.23 -	0.24 3.86%	0.17 29.97%	0.02 89.14%
inventory turnover	18.85 -		20.34 -	12.88 36.69%	16.10 25.03%	9.65 40.08%
invested capital			-0.16 -	0.09 159.90%	0.12 26.76%	254.20M 212,750,541,114.95%
market cap	3.98B -	3.98B 0.00%	4.13B 3.78%	1.38B 66.50%	1.03B 25.65%	5.02B 387.34%
net current asset value	131.09M -		-734.14M -	365.38M 149.77%	196.33M 46.27%	43.87M 77.66%
net debt to ebitda	2.53 -		1.14 -	1.79 56.31%	1.05 41.37%	0.48 53.82%
net income per share	-0.45 -	-0.71 57.64%	-0.45 36.62%	-0.60 33.34%	-0.69 14.74%	-1.40 102.92%
operating cash flow per share	-0.24 -	-0.46 89.34%	-0.18 60.03%	-0.46 152.57%	-0.37 20.62%	-0.35 5.76%
payables turnover	5.65 -		10.34 -	3.66 64.58%	12.77 248.50%	10.39 18.59%
receivables turnover	41.60 -		98.32 -	80.44 18.18%	157.88 96.26%	24.20 84.67%
research and ddevelopement to revenue	0.32 -	0.59 86.19%	0.66 10.43%	0.70 6.28%	0.74 6.71%	0.93 25.80%
return on tangible assets	-0.26 -		-0.41 -	-0.30 26.33%	-0.59 93.92%	-1.95 231.90%
revenue per share	1.08 -	0.75 30.72%	0.60 20.15%	0.75 25.31%	0.66 11.80%	0.46 30.43%
roe	-0.58 -		0.31 -	-0.24 177.15%	-0.44 83.78%	-3.54 710.14%
roic	-0.60 -		0.45 -	-0.23 150.73%	-0.36 57.95%	-1.63 348.91%
sales general and administrative to revenue	0.11 -	0.19 70.45%	0.41 109.06%	0.36 11.89%	0.39 8.13%	0.68 74.38%
shareholders equity per share	0.77 -		-1.47 -	2.53 272.82%	1.58 37.57%	0.40 74.95%
stock based compensation to revenue	0.09 -	0.15 72.62%	0.36 146.97%	0.21 41.22%	0.39 81.81%	0.55 41.28%
tangible asset value	313.29M -		-602.51M -	480.37M 179.73%	301.01M 37.34%	134.75M 55.23%
tangible book value per share	0.77 -		-1.48 -	1.33 189.63%	0.67 49.82%	0.28 57.54%
working capital	327.11M -		191.96M -	448.55M 133.67%	275.58M 38.56%	123.19M 55.30%

COM:23ANDME

23andMe Holding Co.

Last Close

3.23

22/11 21:00

Market Cap

225.52M

Beta: -

Volume Today

514.98K

Avg: -

Preview